top of page
ATH-01 is a first-in-class molecule directed towards clearing plaque cholesterol and lipids from the wall of arteries
The Problem
THE PROBLEM
Atherosclerosis is the build up of cholesterol and other lipids (fats) in the walls of arteries, causing narrowing and blockage where stroke, heart attack, amputation, kidney failure and loss of bowel can result. Atherosclerosis occurs in all of us as we age but more severely if we smoke, have high blood pressure, high cholesterol, diabetes, obesity or live an unhealthy lifestyle.
THE ATHERID SOLUTION
We are developing the first drug to clear cholesterol and other lipids from the walls of arteries. Our drug is based on a naturally occurring protein linked to a smaller molecule which targets it to the plaques. Preclinical studies have shown it to be safe and reduce plaques from blood vessels via a unique mechanism. After 10 years of extensive testing in mice and on human tissue taken from surgery, we are ready to complete final preclinical studies, aiming to commence trials within 2 years.
The Solution
WHO WE HELP
​Our mission is to prevent heart attack, stroke and amputation, and reduce the risk of vascular events and hospitalisation by helping patients to reduce the plaque in their arteries such as:
​
-
Individuals with a genetic predisposition to atherosclerotic disease, including those with homozygous familial hypercholesterolemia,
​​
-
Patients with established peripheral arterial disease (PAD) and/or diabetes. PAD is the process whereby arteries to the legs and other organs develop narrowings from atherosclerosis such as for Trevor (pictured right), one of our consumer advisors.
OUR PARTNERS
bottom of page